LUPIN LIMITED
SAFETY DATA SHEET

Section 1: Identification

Material

Meloxicam Tablets USP
7.5 mg and 15 mg

Manufacturer

Lupin Limited, MADE IN INDIA.

Distributor

Lupin Pharmaceuticals, Inc.
111 South Calvert Street,
Harborplace Tower, 21st Floor,
Baltimore, Maryland 21202
United States
Tel. 001-410-576-2000
Fax. 001-410-576-2221

Section 2: Hazard(s) Identification

Section 2, Hazard(s) identification

Fire and Explosion

Expected to be non-combustible.

Health

Allergic Reactions
Meloxicam is contraindicated in patients with known hypersensitivity (e.g., anaphylactoid reactions and serious skin reactions) to meloxicam.
Meloxicam should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.

Coronary Surgery
Meloxicam is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) Surgery.

Environment

No information is available about the potential of this product to produce adverse environmental effects.

Section 3: Composition/Information on Ingredients

Section 3, Composition/information on ingredients

Ingredients

Meloxicam USP

CAS

71125-38-7
# Section 4: First-Aid Measures

## Section 4, First-aid measures

### Ingestion

If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

### Inhalation

Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

### Skin Contact

Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

### Eye Contact

Flush eyes with plenty of water. Get medical attention.

## NOTES TO HEALTH PROFESSIONALS

### Medical Treatment

Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

### OVERDOSAGE

There is limited experience with meloxicam overdose. Four cases have taken 6 to 11 times the highest recommended dose; all recovered. Cholestyramine is known to accelerate the clearance of meloxicam.

Symptoms following acute NSAID overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Severe poisoning may result in hypertension, acute renal failure, hepatic dysfunction, respiratory depression, coma, convulsions, cardiovascular collapse, and cardiac arrest. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose.

Patients should be managed with symptomatic and supportive care following an NSAID overdose. Administration of activated charcoal is recommended for patients who present 1 to 2 hours after overdose. For substantial overdose or severely symptomatic patients, activated charcoal may be administered repeatedly. Accelerated removal of meloxicam by 4 g oral doses of cholestyramine given three times a day was demonstrated in a clinical trial. Administration of cholestyramine may be useful following an overdose. Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.

For additional information about overdose treatment, call a poison control center (1-800-222-1222).
### Section 5: Fire-Fighting Measures

**Section 5, Fire-fighting measures**

<table>
<thead>
<tr>
<th>Fire and Explosion Hazards</th>
<th>Assume that this product is capable of sustaining combustion.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extinguishing Media</td>
<td>Water spray, carbon dioxide, dry chemical powder or appropriate foam.</td>
</tr>
<tr>
<td>Special Firefighting Procedures</td>
<td>For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.</td>
</tr>
<tr>
<td>Hazardous Combustion Products</td>
<td>Hazardous combustion or decomposition products are expected when the product is exposed to fire.</td>
</tr>
</tbody>
</table>

### Section 6: Accidental Release Measures

**Section 6, Accidental release measures**

<table>
<thead>
<tr>
<th>Personal Precautions</th>
<th>Wear protective clothing and equipment consistent with the degree of hazard.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Environmental Precautions</td>
<td>For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.</td>
</tr>
<tr>
<td>Clean-up Methods</td>
<td>Collect and place it in a suitable, properly labeled container for recovery or disposal.</td>
</tr>
</tbody>
</table>

### Section 7: Handling and Storage

**Section 7, Handling and storage**

<table>
<thead>
<tr>
<th>Handling</th>
<th>No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Store at 20°C to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Keep meloxicam tablets USP in a dry place. Dispense tablets in a tight container. Keep this and all medications out of the reach of children.</td>
</tr>
</tbody>
</table>

### Section 8: Exposure Controls/ Personal Protection

**Section 8, Exposure controls/personal protection**

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.
Section 9: Physical and Chemical Properties

Section 9, Physical and chemical properties

Physical Form

HOW SUPPLIED

Meloxicam Tablets USP are available as light yellow coloured, round, biconvex tablets, plain on one side and debossed with ‘7.5’ on other side containing meloxicam 7.5 mg or as light yellow coloured, oval shaped, biconvex tablets, plain on one side and debossed with ‘15’ on other side containing meloxicam 15 mg.

Meloxicam Tablets USP, 7.5 mg are available as follows:
Bottles of 100 NDC 68180-501-01
Bottles of 1000 NDC 68180-501-03

Meloxicam Tablets USP, 15 mg are available as follows:
Bottles of 100 NDC 68180-502-01
Bottles of 1000 NDC 68180-502-03

Section 10: Stability and Reactivity

Section 10, Stability and reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Section 11, Toxicological information

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis:
There was no increase in tumor incidence in long-term carcinogenicity studies in rats (104 weeks) and mice (99 weeks) administered meloxicam at oral doses up to 0.8 mg/kg/day in rats and up to 8.0 mg/kg/day in mice (up to 0.5- and 2.6-fold, respectively, the maximum recommended human daily dose based on body surface area comparison).

Mutagenesis:
Meloxicam was not mutagenic in an Ames assay, or clastogenic in a chromosome aberration assay with human lymphocytes and an in vivo micronucleus test in mouse bone marrow.

Impairment of Fertility:
Meloxicam did not impair male and female fertility in rats at oral doses up to 9 mg/kg/day in males and 5 mg/kg/day in females (up to 5.8- and 3.2-fold greater, respectively, than the maximum recommended human daily dose based on body surface area comparison).
## Section 12: Ecological Information

No relevant studies identified.

## Section 13: Disposal Considerations

**Incinerate in an approved facility. Follow all federal state and local environmental regulations.**

## Section 14: Transport Information

### IATA/ICAO - Not Regulated
- IATA Proper shipping Name: N/A
- IATA UN/ID No: N/A
- IATA Hazard Class: N/A
- IATA Packaging Group: N/A
- IATA Label: N/A

### IMDG - Not Regulated
- IMDG Proper shipping Name: N/A
- IMDG UN/ID No: N/A
- IMDG Hazard Class: N/A
- IMDG Flash Point: N/A
- IMDG Label: N/A

### DOT - Not Regulated
- DOT Proper shipping Name: N/A
- DOT UN/ID No: N/A
- DOT Hazard Class: N/A
- DOT Flash Point: N/A
- DOT Packing Group: N/A
- DOT Label: N/A

## Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

## Section 16: Other Information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

**Lupin** shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.